Titan Pharmaceuticals (FRA:TN70) EV-to-Revenue : -20.00 (As of Jun. 02, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Titan Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Titan Pharmaceuticals's enterprise value is €-0.02 Mil. Titan Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil. Therefore, Titan Pharmaceuticals's EV-to-Revenue for today is -20.00.

The historical rank and industry rank for Titan Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

FRA:TN70' s EV-to-Revenue Range Over the Past 10 Years
Min: -2164.52 Med: 10.15 Max: 829.24
Current: -173

During the past 13 years, the highest EV-to-Revenue of Titan Pharmaceuticals was 829.24. The lowest was -2164.52. And the median was 10.15.

FRA:TN70's EV-to-Revenue is ranked better than
99.32% of 1035 companies
in the Biotechnology industry
Industry Median: 8.1 vs FRA:TN70: -173.00

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-02), Titan Pharmaceuticals's stock price is €5.917. Titan Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Therefore, Titan Pharmaceuticals's PS Ratio for today is 5,917.00.

Titan Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Titan Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals EV-to-Revenue Chart

Titan Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

32.87

35.03

17.57

150.15

253.38

Titan Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															198.02	173.69	-7.31	253.38	420.89

Competitive Comparison of Titan Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Titan Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Titan Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's EV-to-Revenue falls into.

Titan Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Titan Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	-0.020	/	0.001
	=	-20.00

Titan Pharmaceuticals's current Enterprise Value is €-0.02 Mil.
Titan Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Titan Pharmaceuticals (FRA:TN70) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Titan Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	5.917	/	0.001
	=	5,917.00

Titan Pharmaceuticals's share price for today is €5.917.
Titan Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

Titan Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Titan Pharmaceuticals (FRA:TN70) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (FRA:TN70) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

TTNP:USA

Address

400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080

Website

https://www.titanpharm.com

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Titan Pharmaceuticals (FRA:TN70) Headlines

No Headlines